Clinical Trial: NCT05183126
Pharmacokinetic Study of Skeletal Muscle Area-based Paclitaxel Infusion in Patients With Cancer
Status:
RECRUITINGPhase:
Phase 4| Lead Sponsor: | University of Michigan Rogel Cancer Center |
| Information Provided By: | University of Michigan Rogel Cancer Center |
| Last Update Posted: | 2026-07-02 |
Study Overview
Brief Summary
The primary objective of this pharmacokinetics study is to compare the maximum concentration level of paclitaxel in patients with low/sarcopenic skeletal muscle area (SMA), at the end of a 2-3 hour paclitaxel infusion, to the maximum level in patients with normal SMA at the end of a standard 1-hour infusion with the goal of determining whether lengthening the infusion in patients with low/sarcopenic SMA normalizes the levels to those of patients with normal SMA.
Official Title
Conditions
Intervention / Treatment
- Drug: Paclitaxel
- Drug: Paclitaxel
Other Study ID Numbers
- UMCC 2021.109
- HUM00207945
Start Date (Actual)
Primary Completion Date (Estimated)
Study Completion Date (Estimated)
Enrollment (Estimated)
Study Type
Phase
| Lead Sponsor: | University of Michigan Rogel Cancer Center |
| Information Provided By: | University of Michigan Rogel Cancer Center |
| Last Update Posted: | 2026-07-02 |
Study Overview
Brief Summary
The primary objective of this pharmacokinetics study is to compare the maximum concentration level of paclitaxel in patients with low/sarcopenic skeletal muscle area (SMA), at the end of a 2-3 hour paclitaxel infusion, to the maximum level in patients with normal SMA at the end of a standard 1-hour infusion with the goal of determining whether lengthening the infusion in patients with low/sarcopenic SMA normalizes the levels to those of patients with normal SMA.
Official Title
Conditions
Intervention / Treatment
- Drug: Paclitaxel
- Drug: Paclitaxel
Other Study ID Numbers
- UMCC 2021.109
- HUM00207945